VDMN offers the potential to transform the standard of care for common warts (verruca vulgaris), a viral skin infection caused by human papillomavirus (HPV). Common warts affect approximately 19 million Americans and result in approximately 2.2 million visits with a healthcare provider annually in the U.S. alone. Common warts may persist for years without treatment. Currently, there are no FDA-approved prescription treatments for this condition.

VDMN is an investigational, proprietary, dissolvable microarray patch technology that administers immunotherapy within the superficial aspect of the skin. It is anticipated that this first-in-category technology will provide an “injection-free” immunotherapy treatment for common warts without creating the degree of pain, “needle-phobia,” and anxiety associated with traditional injections. VDMN has the potential to become a preferred treatment approach for children and young adults where aversion to painful procedures involving needles or freezing with liquid nitrogen and common wart prevalence are at their highest.